Biodefense Breaking News: Aethlon Medical (OTCBB:
AEMD) Announces First Treatment of an Ebola Patient
SAN DIEGO - October 14, 2014 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD), announced today the first use of Hemopurifier®
therapy on a patient infected with Ebola virus. The treatment was administered
to a Ugandan doctor at the Frankfurt University Hospital in Germany. The
patient, who is also a World Health Organization (WHO) worker, contracted the
virus in Sierra Leone.
The
Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets
the rapid elimination of viruses and immunosuppressive proteins from the
circulatory system of infected individuals. At present, no antiviral therapy or
vaccine has proven to be effective against Ebola virus infection in humans. The
largest ebola virus epidemic in history is now spreading on a global basis with
more than 4,000 deaths being reported by the WHO.
"We thank the physicians in Frankfurt
for allowing us the opportunity to treat this advanced-stage patient,"
stated Aethlon founder and CEO, Jim Joyce. "Details related to the
patient's response to therapy will be disclosed once hospital officials deem it
appropriate to report an update on the condition of this individual."
In the care of ebola-infected individuals,
the Hemopurifier targets two unmet medical needs: the rapid elimination of
circulating ebola to inhibit continued progeny virus replication and the direct
targeting of shed glycoproteins that overwhelm the host immune response. The
device can be deployed for use within the global infrastructure of dialysis and
CRRT machines already located in hospitals and clinics.
Aethlon further disclosed that it is preparing
to initiate U.S. clinical studies of Hemopurifier therapy based on the United
States Food and Drug Administration's (FDA) approval of an Investigational
Device Exemption (IDE) that was previously submitted by the Company. The study
will contribute safety data to advance the device as a broad-spectrum
countermeasure against pandemic threats, including ebola and chronic viral
pathogens such as HIV and Hepatitis C (HCV).
To date, Hemopurifier therapy has been
successfully administered in approximately one hundred treatment experiences in
health compromised HIV and HCV infected individuals. These studies were
conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and
the Medanta Medicity Institute, all located in India. In vitro validation
studies that demonstrated the ability of the Hemopurifier to capture Zaire and
other strains of ebola virus were conducted by researchers at the United States
Army Medical Research Institute for Infectious Diseases (USAMRIID) and the
United States Centers for Disease Control and Prevention (CDC).
Read this release
in full at http://www.investorideas.com/CO/AEMD/news/2014/10141.asp
About Aethlon Medical, Inc.
Aethlon Medical creates medical devices
that target unmet therapeutic needs in infectious disease and
cancer. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively targets the rapid
elimination of circulating viruses and tumor-secreted exosomes that promote
cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary
that is advancing exosome-based products to diagnose and monitor cancer,
infectious disease and neurological disorders. For more information,
please visit http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain statements herein may be
forward-looking and involve risks and uncertainties. Such forward-looking
statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements
of Aethlon Medical, Inc. to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without limitation,
that the ESI will not be able to commercialize its future products, that the
FDA will not approve the initiation of the Company's clinical programs or
provide market clearance of the company's products, future human studies
whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the
Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness
to established cancer or hepatitis C therapies or as a standalone cancer or
hepatitis C therapy or as a broad spectrum defense against viral pathogens,
including ebola, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The
Investorideas.com newswire is a third party publisher of news and research as
well as creates original content as a news source. Original content created by
investorideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and Linkedintoday plus hundreds
of syndication partners. Our site does not make recommendations for purchases
or sale of stocks or products. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated by featured companies, news submissions, content marketing and
online advertising. Contact each company directly for press release questions.
Disclosure is posted on each release if required but otherwise the news was not
compensated for and is published for the sole interest of our readers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories
24/7 –biotech, mining stocks, oil and gas stocks and more...
